Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial

• Published in: The lancet. Diabetes & endocrinology Vol. 5; no. 5; pp. 333 - 340
• Main Authors: Seferovic, Jelena P, Claggett, Brian, Seidelmann, Sara B, Seely, Ellen W, Packer, Milton, Zile, Michael R, Rouleau, Jean L, Swedberg, Karl, Lefkowitz, Martin, Shi, Victor C, Desai, Akshay S, McMurray, John J V, Solomon, Scott D
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2017
• Subjects: Aged; Aminobutyrates - pharmacology; Aminobutyrates - therapeutic use; Angiotensin II Type 1 Receptor Blockers - pharmacology; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Blood Glucose - drug effects; Cardiology and Cardiovascular Disease; Diabetes Mellitus, Type 2 - complications; Drug Combinations; Enalapril - pharmacology; Enalapril - therapeutic use; Endocrinology & Metabolism; Female; Heart Failure - complications; Heart Failure - drug therapy; Humans; Kardiologi och kardiovaskulära sjukdomar; Male; Middle Aged; Other; Tetrazoles - pharmacology; Tetrazoles - therapeutic use; Valsartan - pharmacology; Valsartan - therapeutic use

Diabetes is an independent risk factor for heart failure progression. Sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor, improves morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), compared with the angiotensin-converting enzyme...